The effects of L-carnitine assisted hemoperfusion combined with hemodialysis on cardiac function and bone metabolism in patients with uremia
Objective To explore the effects of L-carnitine assisted hemoperfusion combined with hemodialysis on cardiac function and bone metabolism in patients with uremia. Methods 80 patients with uremia were divided into a control group and an observation group by random number table method,with 40 cases in each group. The control group was given low-dose L-carnitine (3 g/week) assisted hemoperfusion combined with hemodialysis,and the observation group was given high-dose L-carnitine (4 g/week) assisted hemoperfusion combined with hemodialysis. Patients in both groups were compared in terms of calcium and phosphorus indexes (blood calcium,blood phosphorus),cardiac function indicators[left ventricular ejection fraction (LVEF),fractional shortening (Fs),stroke volume (SV),ratio of early transmitral flow velocity to later transmitral flow velocity (E/A)],bone metabolism indicators and lipid indicators[parathyroid hormone (PTH),alkaline phosphatase (ALP),total cholesterol (TC),and the incidence of adverse reactions. Results After treatment,the observation group had lower blood phosphorus of (1.60±0.45) mmol/L than (1.81±0.42) mmol/L in the control group,and higher blood calcium of (2.25±0.40) mmol/L than (2.05±0.37) mmol/L in the control group (P<0.05). After treatment,the observation group had LVEF of (54.24±1.58)％,Fs of (39.05±0.81)％,SV of (60.84±1.57) ml,and E/A of (1.64±0.21),which were higher than (50.35±1.25)％,(37.84±1.45)％,(59.64±1.76) ml,and (0.85±0.14) in the control group (P<0.05). After treatment,the observation group had ALP of (151.54±5.94) U/L,PTH of (320.75±8.58) pg/ml,and TC of (3.13±1.01) mmol/L,which were lower than (185.64±6.83) U/L,(356.45±9.05) pg/ml,and (4.80±1.34) mmol/L in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). Conclusion The implementation of high-dose L-carnitine (4 g/week) assisted hemoperfusion combined with hemodialysis in patients with uremia can improve the cardiac function of patients and reduce the incidence of abnormal bone metabolism,without an increase in adverse reactions,and is recommended for promotion.
万方数据
维普
